Ocular Therapeutix公司 OCUL 深 滬
等待開盤 11-26 09:30:00 美东时间
12.13
+0.030
+0.25%
華盛通- 最 高12.27
- 今 開12.10
- 成交量 228.45万股
- 最 低 11.77
- 昨 收 12.10
- 總市值 25.72亿
- 52周最高 13.85
- 市盈率 靜 --
- 換手率 1.08%
- 52周最低 5.785
- 委 比 36.01%
- 總股本 2.12亿
- 歷史最高 44.19
- 量 比 0.71
- 振 幅 4.13%
- 歷史最低 1.995
- 每 手 1
- 風險率 2.05%
個股概要
財務分析
公司資料
相關新聞
分紅派息
- 分時圖
- 日k
- 周k
- 月k
相關新聞
更多美股大行评级 | 安捷伦科技、Keysight、先科电子获多家大行上调目标价；摩根大通下调亿航智能评级至"中性"，目标价下调至13美元
今日重点评级关注：HC Wainwright & Co.：维持BiomX"买入"评级，目标价从15美元升至26美元；Clear Street：维持Diversified Energy"买入"评级，目标价从23美元升至25美元
今天 10:07
Ocular Therapeutix Begins Major Trial On Drug That Could Prevent Blindness In Working-Age Diabetics
Ocular Therapeutix, Inc. (NASDAQ:OCUL, "Ocular"))), an integrated biopharmaceutical company committed to redefining the retina experience, today announced that the first patient has been randomized in the HELIOS-3 Phase
11-24 20:12
美股大行评级 | 最高325美元！10家机构集体上调AMD目标价；Pinterest遭14家大行下调目标价；大行对优步目标价分歧大，5家下调5家上调
今日重点评级关注：HC Wainwright & Co.：维持Caribou Biosciences"买入"评级，目标价从3美元升至9美元；HC Wainwright & Co.：上调CervoMed评级至"买入"，目标价从11美元升至25美元
11-06 09:55
Ocular Therapeutix Q3 EPS $(0.38) Misses $(0.37) Estimate, Sales $14.544M Miss $14.627M Estimate
Ocular Therapeutix (NASDAQ:OCUL) reported quarterly losses of $(0.38) per share which missed the analyst consensus estimate of $(0.37) by 3.54 percent. This is a 72.73 percent decrease over losses of $(0.22) per share
11-04 20:06
Earnings Scheduled For November 4, 2025
Companies Reporting Before The Bell • Sequans Communications (NYSE:SQNS) is lik...
11-04 19:12
美股大行评级 | 最高350美元！16家大行上调谷歌目标价！Meta遭12家大行下调目标价；潜在涨幅1456.29%！NRX Pharmaceuticals获Ascendiant Capital升目标价至47美元，维持"买入"评级
今日重点评级关注：Ascendiant Capital：维持NRX Pharmaceuticals"买入"评级，目标价从46美元升至47美元；富国银行：维持Kyverna Therapeutics"超配"评级，目标价从27美元升至31美元
10-31 10:25
TD Cowen Maintains Buy on Ocular Therapeutix, Raises Price Target to $20
TD Cowen analyst Tara Bancroft maintains Ocular Therapeutix (NASDAQ:OCUL) with a Buy and raises the price target from $14 to $20.
10-31 04:14
Oculis to Spotlight Transformative Late-Stage Pipeline at Eyecelerator and AAO 2025
Oculis Holding AG announced its late-stage pipeline will be highlighted at Eyecelerator and the American Academy of Ophthalmology (AAO) Annual Meeting. Key updates includePrivosegtor advancing into registrational trials for acute optic neuritis and non-arteritic anterior ischemic optic neuropathy, OCS-01 eye drops for diabetic macular edema entering Phase 3 trials with expected results in Q2 2026, and Licaminlimab's upcoming PREDICT-1 trial for d...
10-14 08:00
Insider Moves: Ross, Carisma, Agree, Aehr, Ocular
Insiders have been trading these 5 stocks: (($ROST)), (($CARM)), (($ADC)), (($A...
10-11 21:01
美股大行评级 | 最高186美元！戴尔科技或多家机构上调目标价； 高盛上调超微公司目标价至210美元
今日重点评级关注：富国银行：维持Kyverna Therapeutics"超配"评级，目标价从24美元升至27美元；Chardan Capital：维持Oculis Holding"买入"评级，目标价从33美元升至51美元
10-09 10:51
